These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29607465)

  • 1. Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.
    Kasner MT; Mick R; Jeschke GR; Carabasi M; Filicko-O'Hara J; Flomenberg N; Frey NV; Hexner EO; Luger SM; Loren AW; Mangan JK; Wagner JL; Weiss M; Carroll M; Perl AE
    Invest New Drugs; 2018 Aug; 36(4):657-666. PubMed ID: 29607465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.
    Perl AE; Kasner MT; Shank D; Luger SM; Carroll M
    Clin Cancer Res; 2012 Mar; 18(6):1716-25. PubMed ID: 22167413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
    Perl AE; Kasner MT; Tsai DE; Vogl DT; Loren AW; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Frey NV; Nasta SD; Hexner EO; Dierov JK; Swider CR; Bagg A; Gewirtz AM; Carroll M; Luger SM
    Clin Cancer Res; 2009 Nov; 15(21):6732-9. PubMed ID: 19843663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mitoxantrone, etoposide, and cytarabine combination therapy for acute myeloid leukemia patients failing to achieve a complete remission after induction chemotherapy: a single-center experience].
    Morita-Fujita M; Yabushita T; Shimomura Y; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Ishikawa T
    Rinsho Ketsueki; 2018; 59(7):858-864. PubMed ID: 30078794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia.
    Zhong S; Kurish H; Walchack R; Li H; Edwards J; Singh A; Advani A
    Leuk Res; 2024 Apr; 139():107468. PubMed ID: 38460433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
    J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phospho-specific flow: fixating on the target.
    Levis M
    Clin Cancer Res; 2012 Mar; 18(6):1493-5. PubMed ID: 22302900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
    Halpern AB; Othus M; Huebner EM; Buckley SA; Pogosova-Agadjanyan EL; Orlowski KF; Scott BL; Becker PS; Hendrie PC; Chen TL; Percival MM; Estey EH; Stirewalt DL; Walter RB
    Leukemia; 2017 Dec; 31(12):2560-2567. PubMed ID: 28555084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
    Walker AR; Wang H; Walsh K; Bhatnagar B; Vasu S; Garzon R; Canning R; Geyer S; Wu YZ; Devine SM; Klisovic R; Blum W; Marcucci G
    Leuk Lymphoma; 2016 Sep; 57(9):2100-8. PubMed ID: 26784138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
    Advani R; Visani G; Milligan D; Saba H; Tallman M; Rowe JM; Wiernik PH; Ramek J; Dugan K; Lum B; Villena J; Davis E; Paietta E; Litchman M; Covelli A; Sikic B; Greenberg P
    Adv Exp Med Biol; 1999; 457():47-56. PubMed ID: 10500779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.
    Christian S; Arain S; Patel P; Khan I; Calip GS; Agrawal V; Sweiss K; Griffin S; Cahill K; Konig H; Esen A; Shergill A; Odenike O; Stock W; Quigley JG
    Am J Hematol; 2020 Aug; 95(8):937-943. PubMed ID: 32311140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
    Visani G; Milligan D; Leoni F; Chang J; Kelsey S; Marcus R; Powles R; Schey S; Covelli A; Isidori A; Litchman M; Piccaluga PP; Mayer H; Malagola M; Pfister C
    Leukemia; 2001 May; 15(5):764-71. PubMed ID: 11368437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia.
    Marconi G; Talami A; Abbenante MC; Sartor C; Parisi S; Nanni J; Bertamini L; Ragaini S; Olivi M; de Polo S; Cristiano G; Fontana MC; Bochicchio MT; Ottaviani E; Arpinati M; Sessa M; Baldazzi C; Caso L; Testoni N; Baccarani M; Bonifazi F; Martinelli G; Paolini S; Cavo M; Papayannidis C; Curti A
    Eur J Haematol; 2020 Jul; 105(1):47-55. PubMed ID: 32145118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.
    Ho AD; Lipp T; Ehninger G; Illiger HJ; Meyer P; Freund M; Hunstein W
    J Clin Oncol; 1988 Feb; 6(2):213-7. PubMed ID: 3422260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
    Price SL; Lancet JE; George TJ; Wetzstein GA; List AF; Ho VQ; Fernandez HF; Pinilla-Ibarz J; Kharfan-Dabaja MA; Komrokji RS
    Leuk Res; 2011 Mar; 35(3):301-4. PubMed ID: 21109304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
    Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
    Aldoss I; Ji L; Haider M; Pullarkat V
    Acta Haematol; 2014; 131(4):202-7. PubMed ID: 24296475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
    Advani AS; Li H; Michaelis LC; Medeiros BC; Liedtke M; List AF; O'Dwyer K; Othus M; Erba HP; Appelbaum FR
    Leuk Res; 2018 Apr; 67():17-20. PubMed ID: 29407182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.